Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population

► Efficacy results during the first three years of life and individual year follow-up periods of infants participating in this Asian study is reported. ► Efficacy against severe RVGE was 96.9% (95% CI [88.3-99.6]) over the first three years of life and 100% (67.5-100) in RIXX4414 in the third-year. ► RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]).